Safer, continual disinfection
Care222 technology is designed to neutralize pathogens with people present.
Christie CounterAct™ commercial UVC disinfection fixtures contain patented Care222® technology that emits filtered far-UVC 222nm light while meeting established safety guidelines, designed to neutralize pathogens with people present. Care222 is also the world’s first UVC technology with a proprietary optical filter that blocks potentially harmful longer UVC wavelengths from being emitted.
The far-UVC 222nm light that Care222 technology emits provides an added layer of defense against pathogens like the SARS-CoV-2 coronavirus that causes COVID-19. CounterAct CA-20 fixtures are designed for high-ceiling applications, from corporate, government, and education, to transit hubs, cinemas, museums, theme parks and indoor locations, and beyond.
We can work with you to determine how many CounterAct fixtures you need to provide effective coverage of your indoor space. We offer consulting and installation services through our Professional Services group to help with a deployment strategy to add a layer of defense against pathogens in shared indoor spaces.
All references to “disinfect”, “disinfecting” and “disinfection” refer generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition as may be used by any governmental or regulatory authority including the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency. Christie CounterAct products with patented Care222 technology are not medical devices and are not to be used as or for medical devices. The pathogen-reducing efficacy of Christie CounterAct products and their use in occupied spaces is dependent on many site-specific factors as well as proper installation and operation within specifications and in accordance with American Conference of Governmental Institutional Hygienist (ACGIH) guidelines. Professional installation is recommended for Christie CounterAct products. “Christie” is a trademark of Christie Digital Systems USA, Inc., registered in the United States of America and other countries. This product uses Care222® technology developed by Ushio Inc. Care222® is a trademark or registered trademark of Ushio Inc. and Ushio America, Inc.
*Tablet is not included. Android OS only. Recommended tablets for operation: Samsung Galaxy Tab A 8" or 10.1"
Christie CounterAct with Care222 datasheet
Jun 03, 2022 | PDF: 1.7 MB
This document lists the key features and specifications of Christie® CounterAct™.